The chief executive of Scottish healthcare firm Aridhia has said a recent move to its new office at the Queen Elizabeth University Hospital put the company at “the forefront of the precision medicine frontier”.

Aridhia, set up in 2007 by Scottish software entrepreneur David Sibbald, last night officially opened its office in University of Glasgow’s clinical innovation zone in the hospital’s teaching and learning centre.

It will now work closer with current partner Stratified Medicine Scotland Innovation Centre (SMS-IC), also based in the centre, on harnessing data and analytics innovation in biomedical research and precision medicine.

Precision medicine uses the analysis of huge volumes of data covering genes, environment, and lifestyle for patients of diseases such as cancer. Capturing this data and analysing it for trends can lead to breakthroughs in treatment of diseases such as cancer through stratified medicine, uses large groups of patients to predict which treatments cancers are likely to respond to. Its technology can also speed up diagnosis through advanced analytics.

As part of the Government’s Precision Medicine Catapult Programme, the hospital will become Scotland’s only precision medicine centre of excellence.

Chris Roche, chief executive of Aridhia, said this move places the company at the heart of precision medicine activity in Scotland.

All parties will focus on the development of data-driven, operational clinical services that will benefit patients within Scotland and further afield.

“The work happening here in Glasgow, including projects focused on pancreatic cancer, COPD, multiple sclerosis and rheumatoid arthritis, will benefit millions of people around the world, finding better treatments for an array of medical conditions that are targeted to the individual’s needs, faster than ever before,” he said.

“Our new office puts us at the forefront of the precision medicine frontier, and it’s fulfilling to work alongside our peers in Scotland’s national hub for precision medicine, and collaborate so closely on life-changing projects.

Earlier this year, Aridhia signed a contract with a university teaching hospital in the Netherlands which it said would facilitate biomedical research on an “unprecedented scale.”